Queerty is better as a member
This isn’t news … The news from the conference is Sangamo’s “Functional Cure” for HIV/AIDS which is getting virtually no coverage.
Tiny Sangamo BioSciences Inc.’s potential “functional cure” for HIV is getting big attention in advance of a major AIDS scientific meeting.
SB-728-T, a gene therapy designed to knock out the CCR5 receptor on CD4 cells, protects and increases CD4s in patients experiencing poor immunologic recovery while on antiretroviral (ARV) therapy, according to preliminary Phase I study data reported on Monday, February 28, at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. The new results, reported by Jay Lalezari, MD, are among the first from a human study illustrating the therapeutic—and curative—potential of this novel approach being developed by Sangamo BioSciences.
Need an account? Register It's free and easy.
PHOTOS: We Need To Talk About Some Of The Pictures Taken Inside #RNCinCLE
Pizza In Bed, Jake Shears' New Stache & Austin Armacost's Nude Musings
PHOTOS: There Are No Rules Inside Rio's Most Popular Underground Club
PHOTOS: Shirtless Hunks Dip It Low And Pick It Up Slow In Florianópolis
Twitter Responds To The Trump/Pence Announcement And That Dreadful Logo